Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.
Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Rosenbaum E, Kovel S, Pili R, Sinibaldi V, Carducci MA, Hammers H, Eisenberger MA, Sella A. Keizman D, et al. Among authors: pili r. Oncologist. 2012;17(12):1508-14. doi: 10.1634/theoncologist.2012-0125. Epub 2012 Sep 12. Oncologist. 2012. PMID: 22971522 Free PMC article.
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA. Keizman D, et al. Among authors: pili r. Eur J Cancer. 2012 Jan;48(2):202-8. doi: 10.1016/j.ejca.2011.09.001. Epub 2011 Oct 19. Eur J Cancer. 2012. PMID: 22018713 Free PMC article.
Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.
Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Hammers H, Eisenberger MA, Sinibaldi V, Pili R, Hayat H, Kovel S, Sella A, Boursi B, Weitzen R, Mermershtain W, Rouvinov K, Berger R, Carducci MA. Keizman D, et al. Among authors: pili r. Oncologist. 2014 Jan;19(1):51-60. doi: 10.1634/theoncologist.2012-0335. Epub 2013 Dec 5. Oncologist. 2014. PMID: 24309979 Free PMC article.
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA. Keizman D, et al. Among authors: pili r. Eur J Cancer. 2012 May;48(7):1031-7. doi: 10.1016/j.ejca.2012.02.050. Epub 2012 Mar 10. Eur J Cancer. 2012. PMID: 22409947
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
Armstrong AJ, Kaboteh R, Carducci MA, Damber JE, Stadler WM, Hansen M, Edenbrandt L, Forsberg G, Nordle Ö, Pili R, Morris MJ. Armstrong AJ, et al. Among authors: pili r. Urol Oncol. 2014 Nov;32(8):1308-16. doi: 10.1016/j.urolonc.2014.08.006. Epub 2014 Sep 16. Urol Oncol. 2014. PMID: 25240761 Free PMC article. Clinical Trial.
233 results